IP Library Granted Patent US 9,139,538
Granted Patent B2
US 9,139,538 · App. 14/564,263 · Granted Sep 22, 2015

Quinolinyl glucagon receptor modulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,139,538
App. No.
14/564,263
Granted
Sep 22, 2015
Kind
B2
Abstract

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , A 1 , A 2 , A 3 , B 1 , B 2 , B 3 and B 4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Claims (26)

1. A compound of Formula Ia′

or a pharmaceutically acceptable salt thereof, wherein

R 1 is (C 1 -C 6 )alkyl which is optionally substituted with one to three fluoro, hydroxy or methoxy; (C 3 -C 7 )cycloalkyl which is optionally substituted with one to two fluoro or one to two (C 1 -C 3 )alkyl which are each optionally substituted with one to three fluoro and wherein one carbon of the (C 3 -C 7 )cycloalkyl can be replaced with an O; or (C 3 -C 7 )cycloalkyl-(C 1 -C 6 )alkyl wherein the (C 3 -C 7 )cycloalkyl group of said (C 3 -C 7 )cycloalkyl-(C 1 -C 6 )alkyl is optionally substituted with one to two (C 1 -C 3 )alkyl which are each optionally substituted with one to three fluoro;

R 2 is hydrogen or (C 1 -C 3 )alkyl;

R 3 ′ is —(CH 2 ) 2 CO 2 R, —CH 2 CHFCO 2 R, or —CH 2 CH(OH)CO 2 R;

R is (C 1 -C 4 )alkyl, benzyl, para-methoxybenzyl, or diphenylmethylene;

A 1 and A 2 are each independently CR 4 ;

R 4 at each occurrence is independently hydrogen, halo, cyano, (C 1 -C 3 )alkyl optionally substituted with one to three fluoro, (C 1 -C 3 )alkoxy optionally substituted with one to three fluoro, or (C 3 -C 5 )cycloalkyl;

B 1 , B 2 , B 3 and B 4 are each independently CR 5 ; and

R 5 at each occurrence is independently hydrogen, halo, cyano, (C 1 -C 3 )alkyl optionally substituted with one to three fluoro, or (C 1 -C 3 )alkoxy optionally substituted with one to three fluoro, or (C 3 -C 5 )cycloalkyl.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 2 is hydrogen;

R 3 ′ is —(CH 2 ) 2 CO 2 R; and

R is methyl, ethyl, or t-butyl.

3. The compound according to claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 1 is ethyl, propyl, isopropyl, isobutyl, t-butyl, pentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclopropylmethyl each optionally substituted with 1 to 3 fluoro and wherein said cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl are each optionally substituted with 1 to 2 methyl.

4. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein

R 4 at each occurrence is independently hydrogen, fluoro, chloro, methyl or ethyl; and

R 5 at each occurrence is independently hydrogen, fluoro, chloro, methyl, trifluoromethyl or methoxy.

5. A compound of structure

or a pharmaceutically acceptable salt thereof.

6. A compound of structure

or a pharmaceutically acceptable salt thereof.

7. A compound of structure

or a pharmaceutically acceptable salt thereof.

8. A compound of structure

or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →